Open company graph database — free web & API
Login

PeptiDream Inc.

Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
751
Related companies
4
§01

Basic information

BASIC
Head office
〒210-0821 Kanagawa Prefecture, Kawasaki City, Kawasaki-ku, Tonemachi 3-25-23
Chief executive
Lead Patrick
Capital
Employees (non-consolidated)
Employees (consolidated)
751 people
Start date
2006-07-01
End date
§02

Websites

1 DOMAINS
§03

Business

6
Sale of radioactive pharmaceuticalsDevelopment of radioactive therapeutic drugsDevelopment of radioactive diagnostic agentsDevelopment of peptide pharmaceuticalsDevelopment of peptide-drug conjugates (PDC)Development of multifunctional peptide conjugates (MPC)
§04

Related companies

4 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
PDR Pharma Inc.
Group Subsidiary
PeptiStar Inc.
Group
PeptiAID Inc.
Group
Sugi Holdings Co., Ltd.
Alliance
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

29 EVENTS

Founded in Chiyoda Ward, Tokyo, with Yuaki Suga (developer of Flexizyme technology and professor at the University of Tokyo) and Kazuichi Kubota (former chairman of the board), with laboratories inside the University of Tokyo's Center for Advanced Science and TechnologySources

PeptiDream was founded in Tokyo, JapanSources

Acquired exclusive implementation and licensing rights with sublicense rights to Flexizyme and related basic patents from the University of Tokyo, a national university corporationSources

Entered into a sub-licensable exclusive license agreement with the University of Tokyo on Flexizyme TechnologySources

Acquired exclusive implementation and licensing rights with sublicense rights to basic patents related to Flexizyme development from the State University of New YorkSources

Entered into a sub-licensable exclusive license agreement with the State University of New York on Flexizyme TechnologySources

Relocated headquarters to Meguro Ward, Tokyo (inside the University of Tokyo's Center for Advanced Science and Technology)Sources

Relocated corporate headquarters to RCAST (Research Center for Advanced Science and Technology, The University of Tokyo)Sources

Relocated headquarters and laboratory functions to Meguro Ward, Tokyo (inside the University of Tokyo's Komaba Research Campus KOL)Sources

Relocated corporate headquarters and research laboratories to Komaba Research Campus, The University of TokyoSources

Established Peptide Discovery Platform System (PDPS), a proprietary drug discovery platform technologySources

Established its proprietary technology “Peptide Discovery Platform System (PDPS).”Sources

Listed on the Mothers Market of the Tokyo Stock ExchangeSources

Listed on the Tokyo Stock Exchange MothersSources

Changed market to the First Section of the Tokyo Stock ExchangeSources

Listed on the first section of the Tokyo Stock Exchange.Sources

Relocated headquarters and research institute from Meguro Ward, Tokyo (inside the University of Tokyo's Komaba Research Campus KOL) to a new building within the Kings Sky Front, Kawasaki City, Kanagawa, an international strategic hubSources

Relocated corporate headquarters to Tonomachi, Kawasaki City.Sources

Lead Patrick, one of the founding members, who established the foundation technology of PDPS and supervised various research and development programs with pharmaceutical companies as CSO (Chief Science Officer), appointed as President and CEOSources

Patrick C. Reid was appointed as President and CEOSources

PeptiStar Inc. was founded through a joint venture agreement between PeptiDream Inc., Shionogi & Co., Ltd. and Sekisui Chemical Co., Ltd.Sources

Established Peptigrow Co., Ltd., a joint venture with Mitsubishi Corporation to develop, manufacture, and sell peptides that substitute growth factors, essential components of cell culture mediaSources

PeptiGrowth Inc. was founded through a joint venture agreement between PeptiDream Inc. and Mitsubishi Corporation.Sources

Established Peptieid Co., Ltd., a joint venture with Fujitsu Limited, Mizuho Capital Co., Ltd., Takenaka Corporation, and Kishida Chemical Co., Ltd., for the development of COVID-19 therapeutic drugsSources

PeptiAID Inc. was founded through a joint venture agreement between PeptiDream Inc., Fujitsu Limited, Mizuho Capital Co., Ltd., Takenaka Corporation and KISHIDA CHEMICAL CO., LTD.Sources

Acquired PDR Pharma Inc., a new company that inherited the radioactive pharmaceuticals business through a spin-off from Fujifilm Toyama Chemical Co., Ltd.Sources

Fully acquire a newly established company, PDRadiopharma Inc. that succeeds the radiopharmaceutical business of Fujifilm Toyama Chemical.Sources

Changed to the Prime Market of the Tokyo Stock ExchangeSources

Changed to the Prime Market of the Tokyo Stock ExchangeSources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑